<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>Cancer Network Newsletter</title><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#295AA6;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#295AA6;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1027" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body bgcolor="#F0F1F2" lang=EN-CA link="#295AA6" vlink="#295AA6"><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Hi all:</span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for an article on the length of ADT (androgen deprivation therapy) hormone treatment.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><div><p class=MsoNormal><span style='font-size:1.0pt'>Plus: Does ERG expression predict docetaxel benefit in prostate cancer?<o:p></o:p></span></p></div><div id=wrapper><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><span style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>To view this email as a web page, click <a href="http://view.email.cmpmedica-usa.com/?qs=3ee1ff0f72e132cc79b74766b2cb9c40380137b774511cf65baf10257174b6c3edad2faf41228340535578523abb9137954b9d2e65b9fd9507c75d13708c87045757ea4aea27980f"><b><span style='font-size:8.5pt;color:#056C9C'>here.</span></b></a></span><o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#333333;border-spacing: 0'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:#333333;border-collapse:collapse'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><img border=0 width=220 id=networkLogo src="http://www.ubmmedica.com/wp-content/uploads/2016/11/ModernMedicineNetwork-small.png" alt="Modern Medicine Network"><o:p></o:p></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2f65821b0b2641ceda490016d08194cad3da8faf554b2d8c90e4e22a3d9308ac10743cc447ff6f313"><span style='text-decoration:none'><img border=0 width=360 id=logo src="http://images.ubmmedica.com/newsletters/Logos/CancerNetworkLogo.png" alt="Cancer Network"></span></a><o:p></o:p></p></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:#1A357D;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr><td style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><p class=MsoNormal><span style='font-size:9.5pt;font-family:"Arial","sans-serif";color:white'>ASCO 2017 | June 7, 2017 <o:p></o:p></span></p></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=270 style='width:202.5pt;border-collapse:collapse;border-spacing: 0' id=articles><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a27f94e5e1a5821529179b4cb147bdfd8e2f0ee0e6420557ab0fb4a966688010394568db50f2ad3389"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Prostate Cancer Highlights From ASCO 2017</span></b></a> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><em><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Cancer Network</span></em><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'> presents exclusive coverage on prostate cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6. We bring you expert interviews and reports on the latest trials and scientific advances that are changing the way this malignancy is managed and treated. <o:p></o:p></span></p></td></tr><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25cfd3c224af225d259d7ebf68686ce63a7ec0465b6f888e205d3cd4e094d9f65fb054bbb0da5ecd4"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Reducing ADT to 18 Months May Be Sufficient in High-Risk Prostate Cancer</span></b></a> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Androgen deprivation therapy can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to results of a phase III trial. <o:p></o:p></span></p></td></tr><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25cfd3c224af225d259d7ebf68686ce63a7ec0465b6f888e205d3cd4e094d9f65fb054bbb0da5ecd4"><span style='font-family:"Arial","sans-serif";color:#056C9C'> Read more </span></a> <o:p></o:p></p></td></tr></table><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 align=right width=300 style='width:225.0pt;border-collapse:collapse;border:none;margin-top:2.75pt;margin-bottom:2.75pt'><tr><td style='border:none;border-left:solid #F0F1F2 1.5pt;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:8.5pt;font-family:"Arial","sans-serif";color:#333333'>ADVERTISEMENT <o:p></o:p></span></p></td></tr><tr><td style='border:none;border-left:solid #F0F1F2 1.5pt;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><b><span style='font-size:14.5pt;font-family:"Arial","sans-serif";color:#575452'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef60db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab"></a></span></b><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
<v:stroke joinstyle="miter" />
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0" />
<v:f eqn="sum @0 1 0" />
<v:f eqn="sum 0 0 @1" />
<v:f eqn="prod @2 1 2" />
<v:f eqn="prod @3 21600 pixelWidth" />
<v:f eqn="prod @3 21600 pixelHeight" />
<v:f eqn="sum @0 0 1" />
<v:f eqn="prod @6 1 2" />
<v:f eqn="prod @7 21600 pixelWidth" />
<v:f eqn="sum @8 21600 0" />
<v:f eqn="prod @7 21600 pixelHeight" />
<v:f eqn="sum @10 21600 0" />
</v:formulas>
<v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect" />
<o:lock v:ext="edit" aspectratio="t" />
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" alt="" href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef60db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab" style='position:absolute;margin-left:173.8pt;margin-top:0;width:225pt;height:187.5pt;z-index:251658240;mso-wrap-distance-left:3pt;mso-wrap-distance-top:3pt;mso-wrap-distance-right:3pt;mso-wrap-distance-bottom:3pt;mso-position-horizontal:right;mso-position-horizontal-relative:text;mso-position-vertical-relative:line' o:allowoverlap="f" o:button="t">
<v:imagedata src="http://oascnx15005.247realmedia.com/RealMedia/ads/adstream_nx.ads/cancernetworkEnews/CN/Econf/06072017/106072017@x31?_RM_NX_ID_=106072017" />
<w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef60db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab"><img border=0 width=300 height=250 src="http://oascnx15005.247realmedia.com/RealMedia/ads/adstream_nx.ads/cancernetworkEnews/CN/Econf/06072017/106072017@x31?_RM_NX_ID_=106072017" align=right hspace=4 vspace=4 v:shapes="_x0000_s1026"></a><![endif]><b><span style='font-size:14.5pt;font-family:"Arial","sans-serif";color:#575452'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef60db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab"><span style='text-decoration:none'><img border=0 width=1 height=1 id="_x0000_i1027" src="https://ad.doubleclick.net/ddm/ad/N6246.131798.CANCERNETWORK/B10763357.144002873;sz=1x1;ord=12345678;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=?" alt=Advertisement></span></a></span></b><b><span style='font-size:14.5pt;font-family:"Arial","sans-serif";color:#575452'><o:p></o:p></span></b></p></td></tr></table></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2c747cef284d734a33cff03f317e39ae4d739cea04758ef43d2620c6b28b7738370c976c136c4d83b"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?</span></b></a> <o:p></o:p></p></td></tr><tr><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials. <o:p></o:p></span></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2c747cef284d734a33cff03f317e39ae4d739cea04758ef43d2620c6b28b7738370c976c136c4d83b"><span style='font-family:"Arial","sans-serif";color:#056C9C'> Read more </span></a> <o:p></o:p></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a227e63b26bb24f4fd1c05797f61e2c6285c3d4ab528f866f2120f07ecfa09801a785e37fca326bb31"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Signature for Aggressive-Variant CRPC Predicts Platinum Sensitivity</span></b></a> <o:p></o:p></p></td></tr><tr><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>A molecular signature for aggressive-variant prostate carcinoma can predict which men with castrate-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin. <o:p></o:p></span></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a227e63b26bb24f4fd1c05797f61e2c6285c3d4ab528f866f2120f07ecfa09801a785e37fca326bb31"><span style='font-family:"Arial","sans-serif";color:#056C9C'> Read more </span></a> <o:p></o:p></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a211aa6705df2ada895f588b087f5a861a838e687713285c1dbb355256fb04fab52e4ae9419f3bf1f6"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Post-Progression Enzalutamide/Abiraterone Not Effective in Metastatic CRPC</span></b></a> <o:p></o:p></p></td></tr><tr><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Continued enzalutamide with abiraterone failed to improve PFS in men with metastatic castration-resistant prostate cancer who progressed on enzalutamide alone. <o:p></o:p></span></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a211aa6705df2ada895f588b087f5a861a838e687713285c1dbb355256fb04fab52e4ae9419f3bf1f6"><span style='font-family:"Arial","sans-serif";color:#056C9C'> Read more </span></a> <o:p></o:p></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0'><tr><td style='background:#1F7887;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:15.0pt;font-family:"Arial","sans-serif";color:white'>IN CASE YOU MISSED IT <o:p></o:p></span></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a240bcdbb022c83efac678ebcab86a9727e27e0427241c130ffb671cc12403b97cebb1e33225734290"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Abiraterone/ADT Combo Increased Prostate Cancer Survival</span></b></a> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;max-width:90px'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;border-spacing: 0' id=articles><tr><td width=90 valign=top style='width:67.5pt;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><img border=0 width=70 id="_x0000_i1028" src="http://www.cancernetwork.com/sites/default/files/styles/thumbnail_autocrop/public/fizazi-100.jpg" alt="image description here"><o:p></o:p></p></td><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Combined therapy with abiraterone acetate/prednisone plus ADT significantly improved overall survival and radiographic progression-free survival among men with metastatic hormone-naive prostate cancer.<br><br></span><span style='font-size:12.5pt;font-family:"Arial","sans-serif";color:#333333'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a240bcdbb022c83efac678ebcab86a9727e27e0427241c130ffb671cc12403b97cebb1e33225734290"><span style='color:#056C9C'> Read more </span></a></span><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2e80d5815606c963f4dd4632f698ebb570601c05d6b66c1ae2dc7b8ec4c1dc67a366b20ca15ae2753"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>STAMPEDE: Abiraterone Slowed Progression of Advanced Prostate Cancer</span></b></a> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;max-width:90px'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;border-spacing: 0' id=articles><tr><td width=90 valign=top style='width:67.5pt;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><img border=0 width=70 id="_x0000_i1029" src="http://www.cancernetwork.com/sites/default/files/styles/thumbnail_autocrop/public/james-100.jpg" alt="image description here"><o:p></o:p></p></td><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Abiraterone at the start of ADT for men with metastatic prostate cancer significantly improved overall survival and failure-free survival, with manageable toxicity.<br><br></span><span style='font-size:12.5pt;font-family:"Arial","sans-serif";color:#333333'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2e80d5815606c963f4dd4632f698ebb570601c05d6b66c1ae2dc7b8ec4c1dc67a366b20ca15ae2753"><span style='color:#056C9C'> Read more </span></a></span><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr></table></div></td></tr></table><p class=MsoNormal style='background:#F0F1F2'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#323232'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:#323232'><tr><td style='border:none;border-bottom:solid #555555 2.25pt;padding:7.5pt 7.5pt 7.5pt 7.5pt'><p style='line-height:140%'><b><span style='font-size:9.0pt;line-height:140%;font-family:"Arial","sans-serif";color:#888888'>This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.<o:p></o:p></span></b></p></td></tr></table></div></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:#323232' id=footer><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="27%" style='width:27.0%;background:#323232'><tr><td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><p class=MsoNormal><img border=0 id="_x0000_i1030" src="http://images.ubmmedica.com/ubm-logo-newsletter-2017-white.png"><o:p></o:p></p><p style='line-height:140%'><span style='font-size:8.5pt;line-height:140%;font-family:"Arial","sans-serif";color:#888888'>This email was sent by: <b>UBM Medica, a division of UBM Americas</b><br>535 Connecticut Avenue, Suite 300<br>Norwalk, CT, 06854, USA<o:p></o:p></span></p></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="27%" style='width:27.0%;background:#323232' id=footer><tr><td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><p><b><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:#B2B2B2'>NEWSLETTER<o:p></o:p></span></b></p><p style='line-height:140%'><span style='font-family:"Arial","sans-serif";color:#888888'><a href="http://view.email.cmpmedica-usa.com/ftaf.aspx?qs=3ee1ff0f72e132cc79b74766b2cb9c40380137b774511cf65baf10257174b6c3384dfc2e4893893e"><span style='font-size:11.0pt;line-height:140%;color:#BEBEBE;text-decoration:none'>Forward to a Friend</span></a></span> <br><span style='font-family:"Arial","sans-serif";color:#888888'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25f722e1b96d49482accf64cad96d7918a2ae362220c9613b7ddb5fa534472c5e415ae27617ef999b"><span style='font-size:11.0pt;line-height:140%;color:#BEBEBE;text-decoration:none'>Privacy Statement</span></a></span><br><span style='font-family:"Arial","sans-serif";color:#888888'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a29abe7878ff41ea9a4e59ec007104c6a4b82c213662b7ed210020abad4f2191342bed661392c8a30d"><span style='font-size:11.0pt;line-height:140%;color:#BEBEBE;text-decoration:none'>Terms of Service</span></a></span><br><span style='font-family:"Arial","sans-serif";color:#888888'><a href="http://click.email.cmpmedica-usa.com/profile_center.aspx?qs=a2b941f134a42763c587af15301dc42e736c79925b42e448033004340d6a57b430a29de4e55f1ce427262852dab25762c0e351af21d2bb228b271df13599b269"><span style='font-size:11.0pt;line-height:140%;color:#BEBEBE;text-decoration:none'>Update Profile</span></a></span><br><span style='font-family:"Arial","sans-serif";color:#888888'><a href="http://click.email.cmpmedica-usa.com/subscription_center.aspx?qs=a2b941f134a427630194887cedb9930e605e0f336747cef24d07245aca6d7bdd902d355cc35bc0641fa8c26b5fcee8ebb82ae17df9071c6d3e2054c0c7ede358"><span style='font-size:11.0pt;line-height:140%;color:#BEBEBE;text-decoration:none'>Add/Remove Newsletters</span></a></span><br><span style='font-family:"Arial","sans-serif";color:#888888'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a266f29a4e1cfb0aeff931d248575e47ec28d28f115ec5c710f057b0e450fdf8b1dc21685febb9ca3d"><span style='font-size:11.0pt;line-height:140%;color:#BEBEBE;text-decoration:none'>Subscribe to Print</span></a></span><br><span style='font-family:"Arial","sans-serif";color:#888888'><a href="mailto:editorial@hcl.com"><span style='font-size:11.0pt;line-height:140%;color:#BEBEBE;text-decoration:none'>Contact Us</span></a></span> <o:p></o:p></p></td></tr></table><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=right width="38%" style='width:38.0%;background:#323232'><tr><td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><p><b><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:#B2B2B2'>CONNECT<o:p></o:p></span></b></p><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a23d5e991ee4d917c026b0aeeb9c96b33f79503b05d66cbe606dce7eb74bb8d55f077e4d9c477caae4"><span style='text-decoration:none'><img border=0 id="_x0000_i1031" src="http://images.ubmmedica.com/newsletters/social_media/twitter_icon.png" alt=Twitter></span></a> <a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a22829068fba015b386493d7f86ddcf4257481416b9f78ffd660b2e4c1c8860b0f4d7c76d08a6f1460"><span style='text-decoration:none'><img border=0 id="_x0000_i1032" src="http://images.ubmmedica.com/newsletters/social_media/facebook_icon.png" alt=Facebook></span></a> <a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25090947c495c31eed585b712d838f5cee37f4a6210d1fe5134c60c00edd0042eb9d7fec2d8be8487"><span style='text-decoration:none'><img border=0 id="_x0000_i1033" src="http://images.ubmmedica.com/newsletters/social_media/linkedin_icon.png" alt=LinkedIn></span></a> <a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ff6efc02f4d4c8f28764e7e349d8cac690010255eb80150955e9025cae1233fb06b5fb7eb5b1d6a2"><span style='text-decoration:none'><img border=0 id="_x0000_i1034" src="http://images.ubmmedica.com/newsletters/social_media/rss_icon.png" alt=RSS></span></a><o:p></o:p></p></td></tr></table></td></tr></table></div></td></tr><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'><span style='font-size:7.5pt;font-family:"Arial","sans-serif"'> <o:p></o:p></span></p></td></tr></table></div></div><p class=MsoNormal><img border=0 width=1 height=1 id="_x0000_i1035" src="http://click.email.cmpmedica-usa.com/open.aspx?ffcb10-fe6716797766077f7114-fdbb1570736204787d10767d6c-feca15707d60027f-fe98157571670c7d77-fdf01575716504757d12757c-ffcf14"><o:p></o:p></p></div></body></html>